Sustainability

Revolutionising care

Governance

Ethical business culture

We set high standards of ethics and responsibility in our business and act with integrity and care for human rights throughout our value chain. Mölnlycke is a signatory of the UN Global Compact and is committed to responsible business practices. For details see here.

Transparent reporting for informed sustainable decisions

Transparency in reporting is central to our sustainability efforts. We ensure data is accurate, accessible and actionable for our customers and other stakeholders. By refining how we communicate, we address a core need for clarity, enabling informed, sustainable choices across the healthcare sector.

Download Mölnlycke's Annual Report 2024

  • In 2024, we conducted a Double Materiality Assessent (DMA) to enhance our understanding of material sustainability-related impacts, risks and opportunities, in alignment with CSRD requirements for identifying and evaluating ESG-related factors. The validated DMA will inform Mölnlycke’s sustainability roadmap and disclosures. The results of the DMA are presented in the table below.

    The scope of the assessment included all operations of Mölnlycke, including subsidiaries and joint ventures, as well as its upstream and downstream value chain, and was global in geographic scope.

"Recognising the profound and ongoing pressure on environment, society and global healthcare systems in particular, Mölnlycke are accelerating our transformation to deliver sustainable healthcare solutions. We are uniquely positioned to improve patient lives while reducing the environmental impact of healthcare."

Zlatko Rihter Chief Executive Officer

Our commitment to reach Net Zero by 2050

We've formalised our climate change mitigation efforts by publicly committing to the Science Based Targets Initiative (SBTi), and securing their validation of our near-term climate targets, detailed below:

  • Reducing absolute scope 1 and 2 GHG emissions by 50% by 2030 from a 2021 base year.

  • Increasing active annual sourcing of renewable electricity from 23% in 2021 to 100% by the end of 2024 and continuing active annual sourcing of 100% of renewable electricity through 2030.

  • Reducing absolute scope 3 GHG emissions from purchased goods and services (cat. 1), fuel and energy related activity (cat. 3), upstream transportation and distribution (cat. 4) and waste generated in operations (cat. 5) by 20% by 2028 from a 2021 base year.

  • Having 63% of our suppliers by emissions covering purchased goods and services (cat. 1) capital goods (cat. 2), and upstream transportation and distribution (cat. 4) committed to the Science Based Targets Initiative by 2028.

Milestones on the way to Net Zero

 

2016: Scope 1 and 2 GHG emissions measured and baseline established.

2021: Materiality analysis and development of WeCare (2030 sustainability roadmap).

2021: Upstream and downstream scope 3 GHG emissions measured and baseline established.

2021: First range of BARRIER® surgical drapes launched with demonstrable reductions in emissions.

2022: Commitment to SBTi and nine manufacturing sites operating on 100% fossil-free electricity.

2023: Validation of near-term GHG emission reduction targets by SBTi.

2023: Sustainable Product Portfolio Assessment conduced for Operation Room Solutions and Antiseptics portfolios.

2024: 100% renewable electricity at all manufacturing sites and the headqarters